Tenet Healthcare Corp executive Paola M. Arbour, EVP and Chief Information Officer, sold 10,878 shares of common stock on July 27, 2026 in a transaction reported as a sale in open market or private transactions at a weighted average price of $243.90 per share, with individual prices ranging from $243.82 to $244.08. Following this sale, she directly holds 18,413 shares of Tenet Healthcare common stock. The transaction was not marked as made under a Rule 10b5-1 trading plan.
Tenet Healthcare Corp director James L. Bierman reported selling 5,000 shares of Common Stock on July 27, 2026, in an open-market or private transaction at a weighted average price of $244.96 per share. The sales occurred between $244.95 and $245.29 and left him with 31,604 directly owned shares.
THC reports a planned sale of common stock under a Form 144 notice. The filing lists 10,878 shares of common stock held at Fidelity Brokerage Services LLC, with a reported value of 2,653,158.70, to be sold on the NYSE on or after July 27, 2026.
The holder also reports prior acquisitions of common shares through restricted stock vesting as compensation, including 1,697 shares on March 1, 2025 and additional grants of 768, 4,446, and 3,967 shares on dates in February 2026. The section for securities sold during the past three months does not list any transactions.
Tenet Healthcare Corporation (THC) reports a planned sale of 5,000 shares of common stock through Fidelity Brokerage Services LLC. The shares have an aggregate market value of $1,224,808.00, with 86,137,000 shares of common stock outstanding and an approximate sale date of July 27, 2026.
The shares relate to prior restricted stock vesting events on May 22, 2026 (1,318 shares) and May 26, 2026 (3,682 shares), both identified as compensation awards from the issuer.
Tenet Healthcare reported strong results for the quarter ended June 30, 2026. Net operating revenues were $5.628 billion, up 6.8% year over year. Net income available to common shareholders rose to $826 million, or $9.84 per diluted share, from $288 million, or $3.14, in 2025. Adjusted diluted EPS increased 52.2% to $6.12. Consolidated Adjusted EBITDA was $1.304 billion, up 16.3%, with a 23.2% margin, and management indicated this exceeded prior second‑quarter guidance.
Ambulatory Adjusted EBITDA grew to $542 million, while Hospital Adjusted EBITDA increased to $762 million with margin improving to 18.0%, supported by higher acuity and additional Medicaid supplemental revenues. For the first six months, net cash from operations was $2.226 billion. The company repurchased 5.68 million shares for $1.042 billion in the quarter, and the board approved a $2.0 billion expansion of the repurchase program, leaving $2.13 billion authorized. Tenet raised its 2026 outlook, guiding to Adjusted EBITDA of $4.83–$5.03 billion and adjusted free cash flow of $2.725–$3.025 billion.
Tenet Healthcare director J. Robert Kerrey reported open-market sales of company common stock. On May 28, 2026, he sold a total of 5,638 shares in multiple transactions at weighted average prices within ranges from $172.63 to $178.08 per share, as detailed in the footnotes. After these sales, he directly owns 16,804 shares of Tenet Healthcare common stock.
Tenet Healthcare Corporation reported the results of its 2026 Annual Meeting of Shareholders held on May 27, 2026. Shareholders elected all nominated directors to the Board, with each receiving more than 71 million votes in favor and relatively few votes against or abstentions.
Shareholders also approved, on an advisory basis, the Company’s executive compensation, with 62,554,346 votes for and 11,817,273 against, plus a small number of abstentions and broker non-votes. In addition, shareholders ratified the selection of Deloitte & Touche LLP as the independent registered public accountants for the year ending December 31, 2026, with 79,422,386 votes in favor and minimal opposition.
Agarwala Vineeta reported acquisition or exercise transactions in this Form 4 filing.
Tenet Healthcare Corp director Vineeta Agarwala received a grant of 1,188 restricted stock units. These 2026 May Restricted Stock Units were awarded at no cost and are each economically equivalent to one share of Tenet’s common stock.
The units vest on the first anniversary of the grant date, aligning Agarwala’s compensation with the company’s future performance. After this grant, she holds 1,188 restricted stock units directly. She may elect to receive up to 37% of the vested units in cash instead of shares.
Blunt Roy reported acquisition or exercise transactions in this Form 4 filing.
Tenet Healthcare director Roy Blunt received a grant of 1,188 restricted stock units as compensation. These 2026 May Restricted Stock Units were awarded at a price of $0.00 per unit and are economically equivalent to 1,188 shares of Tenet common stock.
The units vest on the first anniversary of the grant date, so they are scheduled to vest on May 27, 2027, if service-based conditions are met. After this grant, Blunt holds 1,188 restricted stock units directly. He may elect to receive up to 37% of these vested units in cash instead of shares, which gives some flexibility in how the award is settled.
MARK RICHARD J reported acquisition or exercise transactions in this Form 4 filing.
Tenet Healthcare director Richard J. Mark received a grant of 1,188 restricted stock units. The 2026 May RSUs were awarded at no cost and are equivalent to 1,188 shares of common stock. They vest on the first anniversary of the grant, and up to 37% may be settled in cash instead of shares.